ARTICLE | Clinical News
OPA-6566: Phase I/II started
September 19, 2011 7:00 AM UTC
Acucela Inc. (Seattle, Wash.) began a single-blind, placebo-controlled, dose-escalation, U.S. Phase I/II trial in about 120 patients comparing OPA-6566 vs. daily latanoprost. Patients will receive OP...